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Abstract. 
 
The sarcoglycans are a complex of four 
transmembrane proteins (
 
a
 
, 
 
b
 
, 
 
g
 
, and 
 
d
 
) which are pri-
marily expressed in skeletal muscle and are closely as-
sociated with dystrophin and the dystroglycans in the 
muscle membrane. Mutations in the sarcoglycans are 
responsible for four autosomal recessive forms of mus-
cular dystrophy. The function and the organization of 
the sarcoglycan complex are unknown. We have used 
coimmunoprecipitation and in vivo cross-linking tech-
niques to analyze the sarcoglycan complex in cultured 
mouse myotubes. We demonstrate that the interaction 
between 
 
b
 
- and 
 
d
 
-sarcoglycan is resistant to high con-
centrations of SDS and 
 
a
 
-sarcoglycan is less tightly as-
sociated with other members of the complex. Cross-
linking experiments show that 
 
b
 
-, 
 
g
 
-, and 
 
d
 
-sarcoglycan 
are in close proximity to one another and that
 
d
 
-sarcoglycan can be cross-linked to the dystroglycan 
complex. In addition, three of the sarcoglycans (
 
b
 
, 
 
g
 
, 
and 
 
d
 
) are shown to form intramolecular disulfide 
bonds. These studies further our knowledge of the 
structure of the sarcoglycan complex. Our proposed 
model of their interactions helps to explain some of the 
emerging data on the consequences of mutations in the 
individual sarcoglycans, their effect on the complex, 
and potentially the clinical course of muscular dystro-
phies.
Key words: sarcoglycans ¥ muscular dystrophy ¥ im-
munoprecipitation ¥ cross-linking ¥ disulfide bonds
 
T
 
he
 
 dystrophinÐglycoprotein complex (DGC)
 
1
 
 con-
sists of at least ten different proteins located at
the sarcolemma and is critical for the stability of
the muscle membrane (Ervasti et al., 1990; Yoshida and
Ozawa, 1990; Ervasti and Campbell, 1991). The DGC can
be subdivided into three subcomplexes according to their
biochemical characteristics (Yoshida et al., 1994). The cy-
toplasmic component consists of three intracellular pe-
ripheral membrane proteins: dystrophin, syntrophin, and
dystrobrevin. Dystrophin is a 427-kD rod-shaped protein
that binds F-actin (Hoffman et al., 1987; Koenig et al.,
1988; Hemmings et al., 1992; Ervasti and Campbell, 1993).
The syntrophins are a multigene family of at least three
homologous proteins of 58 kD that are directly associated
with dystrophin (Ahn and Kunkel, 1995; Suzuki et al.,
1995). Dystrobrevin is an 80-kD dystrophin-related pro-
tein which is also associated with dystrophin (Sadoulet-
Puccio et al., 1997). Mutations in the dystrophin gene are
the cause of Duchenne and Becker muscular dystrophy
(Monaco et al., 1986; Koenig et al., 1987). The second
subcomplex in the DGC is the dystroglycan complex,
comprised of two closely associated subunits, 
 
a
 
- and 
 
b
 
-dys-
troglycan (Ibraghimov-Beskrovnaya et al., 1992). 
 
a
 
-Dys-
troglycan is a 156-kD extracellular matrix protein that
binds to laminin (Ervasti and Campbell, 1993). 
 
b
 
-Dystro-
glycan is a 43-kD transmembrane protein that binds di-
rectly to the carboxyl terminus of dystrophin via its intra-
cellular tail (Suzuki et al., 1994; Jung et al., 1995). Both
dystroglycans are translated from a single mRNA and are
expressed in many tissues (Ibraghimov-Beskrovnaya et al.,
1993).
The third complex contains a group of transmembrane
proteins called sarcoglycans (Yoshida et al., 1994). Unlike
the dystroglycans, their expression is mostly restricted to
skeletal muscle. Five sarcoglycans have been isolated and
characterized to date (
 
a
 
, 50 kD; 
 
b
 
, 43 kD; 
 
g
 
, 35 kD; 
 
d
 
, 35 kD;
and 
 
e
 
,
 
 50 kD). Four of them (
 
a
 
, 
 
b
 
, 
 
g
 
, and 
 
d
 
)
 
 are known to
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1. 
 
Abbreviations used in this paper:
 
 
 
a
 
-dys, 
 
a
 
-dystroglycan; 
 
b
 
-dys, 
 
b
 
-dystro-
glycan; 2-D, two-dimensional; DGC, dystrophinÐglycoprotein complex;
DSP, dithiobis (succinimidylpropionate); DTSSP, dithiobis (sulfosuccin-
imidylpropionate); EGS, ethylene glycolbis (sulfosuccinimidylsuccinate);
sar, sarcoglycan. 
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be part of the DGC in the sarcolemma of skeletal muscle
(Roberds et al., 1993; Bnnemann et al., 1995; Lim et al.,
1995; Jung et al., 1996; Nigro et al., 1996
 
b
 
; Ettinger et al.,
1997; McNally et al., 1998). The sarcoglycans have been
demonstrated to be closely associated with dystrophin
(Suzuki et al., 1992; Cox et al., 1994; Greenberg et al.,
1994) and the dystroglycan complex (Rafael et al., 1996).
It has been proposed that the DGC links the actin
cytoskeleton with the extracellular matrix (Ohlendieck,
1996) and the proper maintenance of this connection is
thought to be crucial to the mechanical stability of the sar-
colemma (Ervasti and Campbell, 1993; Campbell, 1995).
Although it is not clear how the sarcoglycans might be in-
volved in this linkage, mutations in any one of the four
sarcoglycans often lead to the concomitant loss of the
other sarcoglycans and are responsible for four autosomal
recessive forms of muscular dystrophy (Roberds et al.,
1994; Bnnemann et al., 1995; Lim et al., 1995; Noguchi
et al., 1995; Nigro et al., 1996
 
a
 
). Even in Duchenne and
Becker muscular dystrophy in which the primary defect is
in the dystrophin gene, the sarcoglycans are often absent
or greatly reduced at the membrane as shown by immu-
nofluorescence (Ohlendieck and Campbell, 1991; Ohlen-
dieck et al., 1993). Despite intensive study, the function of
the sarcoglycans remains elusive. They have no homo-
logues in the electronic databases and experiments de-
signed to explore the structure of the sarcoglycan complex
have provided only few clues to their molecular organiza-
tion. The sarcoglycans can be copurified as a subcomplex
from rabbit skeletal muscle but only 
 
b
 
-, 
 
g
 
-, and 
 
d
 
-sarcogly-
can can be chemically cross-linked to each other (Yoshida
et al., 1994, 1997). In vitro expression of the extracellular
portions of the sarcoglycans demonstrated that these do-
mains interact with each other and as well as with the dys-
troglycans in coimmunoprecipitation and blot overlay ex-
periments (Sakamoto et al., 1997).
In this report, we have investigated the molecular or-
ganization of the sarcoglycan complex in cultured mouse
myotubes. Coimmunoprecipitation experiments under dif-
ferent stringencies suggest that 
 
a
 
-sarcoglycan is loosely as-
sociated with the other sarcoglycans whereas the interac-
tion between 
 
b
 
- and 
 
d
 
-sarcoglycan is particularly strong. In
vivo cross-linking experiments have demonstrated that 
 
b
 
-,
 
g
 
-, and 
 
d
 
-sarcoglycan can cross-link to form two major
subcomplexes. We have also shown that 
 
d
 
-sarcoglycan can
be cross-linked to the dystroglycan complex and of the
four sarcoglycans, only 
 
b
 
-, 
 
g
 
-, and 
 
d
 
-sarcoglycan contain
intramolecular disulfide bonds. All together, these infor-
mation should increase our understanding of the sarcogly-
can complex and may shed light on its potential functions
and pathophysiological role in muscular dystrophy.
 
Materials and Methods
 
Mouse Tissue Culture 
 
Primary myoblasts were established from normal mouse skeletal muscle
and grown on 100-mm plates in HamÕs F-10 media supplemented with
20% fetal bovine serum, 2 mM 
 
l-
 
glutamine, 50 
 
m
 
g ml
 
2
 
1
 
 streptomycin, 50
U/ml
 
2
 
1
 
 penicillin (all purchased from Sigma Chemical Co., St. Louis, MO)
and 2.5 ng ml
 
2
 
1
 
 basic fibroblast growth factor (Promega, Madison, WI).
All plates were coated with 40 
 
m
 
g ml
 
2
 
1
 
 extracellular matrix containing en-
tactin, collagen IV, and laminin (Upstate Biotechnology, Lake Placid,
NY) and the cultures were incubated at 37
 
8
 
C with 5% CO
 
2
 
. When the
myoblasts reached confluency, the media was switched to DME (Sigma
Chemical Co.) supplemented with 2% horse serum to induce differentia-
tion. Myoblasts would normally fuse to form myotubes after 3Ð6 d.
 
Preparation of Microsomes
 
To minimize protein degradation, membrane microsomes were prepared
at 4
 
8
 
C according to the method of Mitchell (Mitchell et al., 1983). In brief,
 
z
 
1 g of human skeletal muscle (or four 100-mm plates of cultured mouse
myotubes) was homogenized with a Dounce homogenizer in 5 ml of ice-
cold buffer A (10% sucrose, 0.5 mM EDTA, pH 7.2, 1 mM PMSF and 1
 
3
 
protease inhibitor cocktail purchased from Boehringer Mannheim [Mann-
heim, Germany]). The homogenate was centrifuged at 1,000 
 
g
 
 for 10 min
and the pellet was rehomogenized two additional times using fresh buffer
A. The supernatant from each round of homogenization was subsequently
combined and recentrifuged at 12,000 
 
g
 
 for 10 min. The pellet which con-
tained mostly lysosomes and mitochondria was discarded. Microsomes
were pelleted from the postlysosomal supernatant by centrifugation at
105,000 
 
g
 
 for 1 h using a Beckman SW 28 rotor (Palo Alto, CA). To re-
move proteins that were nonspecifically attached to the pellet, the mi-
crosomes were washed with 150 mM Tris and 0.5 M KCl and then recen-
trifuged at 105,000 
 
g
 
 for 1 h.
 
Preparation of Cell Lysates and Immunoprecipitation
 
Cultured mouse myotubes from a 100-mm plate were washed three times
with 1
 
3 
 
PBS and lysed on ice for 15 min in 1 ml of lysis buffer (50 mM
Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS 1 mM PMSF and 1
 
3
 
protease inhibitor cocktail). Cell lysates were collected by centrifugation
at 15,000 
 
g
 
 for 10 min at 4
 
8
 
C. Protein concentration was determined by the
Bio-Rad DC protein colorimetric assay using bovine serum albumin as
standard (Hercules, CA). For immunoprecipitation experiments, 50Ð100 
 
m
 
g
of cell lysate was first precleared with 50 
 
m
 
l of protein GÐSepharose beads
(Sigma Chemical Co.) for 1 h at 4
 
8
 
C. After centrifugation at 10,000 
 
g
 
 for 2
min, the precleared cell lysate was incubated with 2.5 
 
m
 
l of anti-sarcogly-
can antibody on ice for 4 h and then with 10 
 
m
 
l of protein GÐSepharose
beads on ice for 1 h. The immune complex was pelleted by centrifugation
at 10,000 
 
g
 
 for 2 min and washed three times with 1 ml of ice-cold lysis
buffer. The final pellet was solubilized in 10 
 
m
 
l of 2
 
3
 
 protein sample
buffer (Novex, San Diego, CA) and loaded on 4Ð20% denaturing gradient
gels (Novex). Note that the concentration of SDS in the lysis buffer was
varied in some experiments.
 
Antibodies
 
Mouse monoclonal antibodies directed against 
 
a
 
-sarcoglycan (NCLÐa-sarc);
 
b
 
-sarcoglycan (NCLÐb-sarc), 
 
g
 
-sarcoglycan (NCLÐg-sarc), 
 
d
 
-sarcoglycan
(NCLÐd-sarc), 
 
b
 
-dystroglycan (NCLÐb-DG), and dystrophin (NCL-dys2)
were all purchased from Novocastra (Newcastle-upon-Tyne, UK) and
each was diluted 1:100 for Western blotting and 1:200 for immunohis-
tochemistry. AntiÐ
 
a
 
-dystroglycan antibody (clone VIA4-1) and anti-actin
antibodies (A-2066 and A-4700) were from Upstate Biotechnology and
Sigma Chemical Co., respectively. Each was used in a dilution of 1:1,000
for Western blot analysis. Mouse monoclonal antibody against syntrophin
was obtained from S.C. Froehner (University of North Carolina, Chapel
Hill, NC) (Froehner et al., 1987) and the rabbit polyclonal antibody
against 
 
d
 
-sarcoglycan was a generous gift from V. Nigro (Second Univer-
sity of Naples, Naples, Italy) (Nigro et al., 1996
 
b
 
). Both antibodies were
used at a dilution of 1:5,000 for Western blot analysis. The rabbit poly-
clonal antibody against dystrophin, 6Ð10, has been characterized previ-
ously (Lidov et al., 1990).
 
Immunoblot Analysis 
 
Proteins were transferred from SDS-PAGE gels to nitrocellulose mem-
branes (Schleicher & Schuell, Keene, NH) in Towbin buffer at 20 V at
room temperature (Towbin et al., 1979). Membranes were blocked in
western buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20,
and 0.5% gelatin) for 2 h at room temperature and then incubated with
primary antibodies diluted in Western buffer for another 2 h. After exten-
sive washing in Western buffer, the membranes were incubated for 1 h
with a horseradish peroxidase-conjugated donkey antiÐrabbit (or antiÐ
mouse) IgG (H 
 
1 
 
L) secondary antibody diluted at 1:10,000 in the West-
ern buffer (Jackson ImmunoResearch Laboratories, West Grove, PA).
The horseradish peroxidase-conjugated protein complex was detected by 
Chan et al. 
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enhanced chemiluminescence according to the manufacturerÕs protocol
(Amersham Corp., Arlington Heights, IL).
 
In Vivo Cross-linking of Mouse Myotubes 
 
Cultured mouse myotubes from a 100-mm plate were washed three times
with 1
 
3
 
 PBS and cross-linked with 1 mM dithiobis (sulfosuccinimidylpro-
pionate) (DTSSP) or 1 mM sulfo-ethylene glycolbis (sulfosuccinimidyl-
succinate) (EGS) (Pierce Chemical Co., Rockford, IL) in 50 mM Hepes,
pH 7.5. After a 30-min incubation at 37
 
8
 
C, the reaction was quenched in
5 mL of 1 M Tris, pH 7.4, for 15 min. The cross-linked myotubes were then
washed three times with 1
 
3 
 
PBS and lysed on ice as described above.
DTSSP cross-linked products can be cleaved by reduction with 10 mM
DTT for 30 min at 37
 
8
 
C. Sulfo-EGS cross-linked products can be cleaved
by incubation with 1 M hydroxylamine for 4 h at 37
 
8
 
C, pH 8.5.
 
Two-dimensional Diagonal Gel Electrophoresis
 
Cell lysates prepared from DTSSP cross-linked mouse myotubes were
separated by electrophoresis on 4Ð20% denaturing gradient gel (Novex)
under nonreducing conditions in the first dimension. Each lane was cut
into a strip and soaked in a reducing buffer of 0.1 M DTT, 0.1% SDS, 70 mM
Tris, pH 6.7, and 10% glycerol at room temperature for 1 h. The reduced
strip was then placed on top of a 4Ð20% denaturing gradient slab gel
(Novex) and electrophoresed under reducing conditions in the second di-
mension. The identity of the cross-linked proteins was determined by
Western blots using different anti-sarcoglycan antibodies. A replicate blot
with known molecular weight standards was used to estimate the molecu-
lar mass of the proteins in each dimension.
 
Immunofluorescent Analysis of Muscle Biopsies
 
Muscle biopsies taken from autosomal recessive muscular dystrophy pa-
tients were frozen in isopentane cooled in liquid nitrogen and stored at
 
2
 
80
 
8
 
C until cryosectioning. Thaw-mounted sections (7 
 
m
 
m) were fixed in
methanol for 1 min and blocked in 1
 
3 
 
PBS with 10% fetal calf serum and
0.1% Triton X-100 for 30 min at 4
 
8
 
C. Incubation with primary anti-
sarcoglycan and anti-dystrophin antibodies (1:200 dilution) was carried
out at 4
 
8
 
C for overnight. The slides were washed three times for 20 min
with 1
 
3 
 
PBS, reblocked, and then incubated for 1 h at room temperature
with a Cy3-conjugated donkey antiÐrabbit (or antiÐmouse) IgG (H 
 
1 
 
L)
secondary antibody adsorbed for human with multilabel from Jackson Im-
munoResearch Laboratories (diluted 1:300 in 1
 
3
 
 PBS). After washing
with 1
 
3 
 
PBS three times for 20 min, the slides were coverslipped with Im-
munomount (Shandon, Pittsburgh, PA) and examined using a Leitz Or-
thoplan fluorescence microscope with epi-illumination (Ernst Leitz,
Wetzlar, Germany).
 
Results
 
Sarcoglycans Are Localized to the Membrane Fraction 
of Differentiated Mouse Myotubes
 
Cell culture has been used widely as a model for studying
the DGC. Localization of dystrophin to the cell membrane
has been demonstrated by expression of recombinant dys-
trophin in COS cells, mouse C2C12 cells and mouse mdx
myogenic cultures (Lee et al., 1991; Clemens et al., 1995;
Kumar-Singh and Chamberlain, 1996). Previous studies
have shown that both endogenous dystrophin and 
 
a
 
-sar-
coglycan are localized to the sarcolemma of rat L6 myo-
tubes (Yoshida et al., 1998). In this report, we have used
primary myoblasts established from skeletal muscle of
normal mouse to study the organization of the sarcoglycan
complex. Upon reaching confluency, mouse myoblasts in
culture fuse to form multinucleated myotubes and begin to
express skeletal muscle-specific proteins (Hauschka, 1994).
The expression of the DGC in the differentiated myo-
tubes was confirmed by immunoblotting of the cell lysates
with antibodies against components of the DGC (data not
shown).
To determine if the DGC in primary mouse myotube
culture is localized to the cell membrane, membrane mi-
crosomes were prepared from myotubes culture (Fig. 1,
row 
 
A). Western analysis showed that all the components
of the DGC were found in the microsomal fraction (Fig. 1,
lane 3) but not in the soluble protein fraction (lane 2).
Similar results were obtained from mouse C2C12 myo-
tubes (data not shown). Microsomes prepared in the same
way from human skeletal muscle were shown to contain all
the components of the DGC as expected (Fig. 1, row B,
lane 3).
When cell lysate from cultured mouse myotubes was im-
munoprecipitated with an anti-dystrophin antibody, 6Ð10,
the immune complex was found to contain proteins recog-
nized by antibodies against dystrophin, the syntrophins
and  a-, b-, g-, and d-sarcoglycan but not actin (Fig. 2). Nei-
ther filamin nor troponin was coimmunoprecipitated by
the 6Ð10 antibody (data not shown). Since the DGC is de-
fined by copurification with dystrophin, the coimmunopre-
cipitation of the DGC and dystrophin which is normally at
the sarcolemma implied that these components form a sta-
ble complex on the plasma membrane of mouse myotubes.
The assembly of the DGC at the membrane of mouse myo-
tubes and its similar biochemical characteristics to human
skeletal muscle provides an ideal cell culture system to ex-
plore the sarcoglycan complex.
a-, b-, g-, and d-Sarcoglycan Exist As a Complex in 
Mouse Myotubes
The sarcoglycans have been shown to copurify as a sub-
complex from rabbit skeletal muscle (Yoshida et al., 1994).
Figure 1. Localization of the DGC. Cultured mouse myotubes
(row A) and human skeletal muscle (row B) were used as starting
materials to purify microsomes. Lane 1, unlysed cell pellet frac-
tion after 1,000 g centrifugation. Lane 2, soluble protein fraction
after 105,000 g centrifugation. Lane 3, microsome fraction. The
composition of each fraction was determined by Western blots
using antibodies (18 Ab) against the components of the DGC.
Note that some a-dystroglycan from human skeletal muscle was
found in the soluble protein fraction which is probably due to the
presence of an extensive extracellular matrix network in human
tissue but not in cell culture. Also note that actin can exist as both
unpolymerized monomers in the cytoplasm (soluble protein frac-
tion) and filaments associated with the membrane (microsome
fraction).The Journal of Cell Biology, Volume 143, 1998 2036
To determine if the sarcoglycans could also be purified as
a complex from mouse myotubes, cell lysate prepared
from mouse myotubes was immunoprecipitated with anti-
bodies against different sarcoglycans followed by Western
analysis. All four sarcoglycans were coprecipitated when
an antibody against b-sarcoglycan (NCLÐb-sarc) was used
(Fig. 3), thus verifying that a-, b-, g-, and d-sarcoglycan
form a complex in the mouse myotubes.
When other anti-sarcoglycan antibodies were used as
the primary immunoprecipitation reagents, the sarcogly-
cans being coimmunoprecipitated from the same cell lysate
sample was different in each case (Fig. 3). A polyclonal
antiÐd-sarcoglycan antibody was shown to coimmunopre-
cipitate only b- and d-sarcoglycan but not a- and g-sar-
coglycan from the mouse myotubes cell lysate. An antiÐ
a-sarcoglycan antibody (NCLÐa-sarc) apparently only
immunoprecipitated a-sarcoglycan while an antiÐg-sar-
coglycan antibody (NCLÐg-sarc) only immunoprecipitated
g-sarcoglycan. This immunoprecipitation data suggests
that there is a preferential association between b- and
d-sarcoglycan.
b- and d-Sarcoglycan Are Preferentially Associated with 
One Another
To examine the interaction between b- and d-sarcoglycan
more closely, the sarcoglycan complex was disrupted in
the presence of different concentrations of SDS. Proteins
immunoprecipitated by the antiÐb-sarcoglycan antibody
were immobilized on protein GÐSepharose beads and
washed with buffers containing different concentrations of
SDS. The final composition of the post-SDSÐwashed im-
mune complex was then determined by Western blot using
different anti-sarcoglycan antibodies. All four sarcogly-
cans were present in the immunoprecipitated complex af-
ter being washed with buffer containing no SDS (Fig. 4 a,
lane 2) or 0.2% SDS (lane 3). However, increasing the
SDS concentration in the washing buffer to 0.3% or above
caused the complete dissociation of a-sarcoglycan from
the complex (Fig. 4 a, lane 4 and 5, respectively). A slight
reduction in the amount of g-sarcoglycan in the complex
was also observed at 0.3% SDS washing conditions (Fig. 4
a, lane 4). Further dissociation of g-sarcoglycan was seen
when the immune complex was washed with 0.4% SDS
(lane 5). b- and d-Sarcoglycan remained relatively well as-
sociated even after the immune complex was washed with
0.4% SDS (Fig. 4 a, lane 5).
To increase the stringency of the disruption of the
sarcoglycan complex, mouse myotubes were lysed in dif-
ferent concentrations of SDS for 1 h before immunopre-
cipitation was carried out. Under these conditions, the
sarcoglycan complex was likely to undergo further dissoci-
ation due to the prolonged exposure to high concentra-
tions of SDS. Similar to the results shown above, all four
sarcoglycans were detected in the immunoprecipitated
complex when mouse myotubes were lysed under rela-
tively mild conditions with no SDS, 0.1% or 0.2% SDS
(Fig. 4 b, lanes 2Ð4). a-Sarcoglycan was completely sepa-
rated from the complex when myotubes were lysed at ei-
ther 0.3 or 0.4% SDS (Fig. 4 b, lanes 5 and 6). However, in
contrast to the previous observation that washing the im-
mune complex with 0.3% SDS only caused a mild dissocia-
tion of g-sarcoglycan from the complex (Fig. 4 a, lane 4), a
drastic reduction of g-sarcoglycan in the complex was
observed when myotubes were lysed in 0.3% SDS (Fig. 4
b, lane 5). The amount of b- and d-sarcoglycan found in
the immunoprecipitated complex was also reduced to a
greater extent in the more stringent conditions but never-
theless, a substantial amount of both sarcoglycans were
still associated with one another (Fig. 4 b, lane 5). When
the concentration of SDS in the lysis buffer was increased
to 0.4%, all evidence of the immunoprecipitation was lost
probably because such stringent conditions abolished the
binding of the antibody to its antigen or the binding of the
immune complex to the protein GÐSepharose beads.
The same pattern of sarcoglycan dissociation was ob-
served when immunoprecipitation was performed on cell
lysates prepared from other cell lines, such as murine
C2C12 cells or a normal mouse cell line transformed with
v-myc (data not shown). In addition, the experiment was
repeated on cultured human myotubes using a human
d-sarcoglycanÐspecific antibody (NCLÐd-sarc). As with
the antiÐb-sarcoglycan antibody, the complex immunopre-
cipitated by this antibody under low stringency also con-
tained all four sarcoglycans. When the SDS concentration
Figure 2. Coimmunoprecip-
itation of the sarcoglycans
with dystrophin. Cell lysate
from cultured mouse myo-
tubes was immunoprecipi-
tated by the anti-dystrophin
antibody, 6Ð10. The immune
complex was analyzed by
Western blots using antibod-
ies (18 Ab) against the
sarcoglycans, dystrophin, the
syntrophins, and the actin.
Lane  1, cell lysate from
mouse myotubes (11% in-
put). Lane 2, immunoprecipi-
tated products. Note that
a-sarcoglycan was the least
efficiently precipitated com-
ponent of the DGC.
Figure 3. Coimmunoprecipitation of the sarcoglycans using dif-
ferent anti-sarcoglycan antibodies. Cell lysate from cultured
mouse myotubes were immunoprecipitated by an antibody di-
rected against a-, b-, g-, or d-sarcoglycan. The immune complex
was analyzed by Western blots using antibodies (18 Ab) against
different sarcoglycans. Lane 1, cell lysate from mouse myotubes
(13Ð16% input). Lane 2, immunoprecipitated products. Note that
different sarcoglycans were precipitated by different anti-
sarcoglycan antibodies.Chan et al. Sarcoglycan Complex in Cultured Mouse Myotubes 2037
in the lysis buffer was increased above 0.2%, both a- and
g-sarcoglycan were found to dissociate from the complex
but b- and d-sarcoglycan remained bound together (data
not shown).
Sarcoglycans in Mouse Myotubes Can Be Cross-linked 
In Vivo
Proteins that are tightly associated or in close proximity
with one another can frequently be cross-linked with
chemical reagents. To explore the spatial relationship of
the sarcoglycans in the DGC, cultured mouse myotubes
were cross-linked with 1 mM DTSSP (Jung and Moroi,
1983). Both uncross-linked and DTSSP cross-linked mouse
myotubes were lysed in 0.3% SDS and then immuno-
precipitated with the antiÐb-sarcoglycan antibody. Cross-
linked proteins immunoprecipitated from the DTSSP-
treated myotubes were cleaved with 10 mM DTT before
loading on SDS-PAGE gels. Western blots of the immu-
noprecipitated complex from uncross-linked myotubes
showed that only b- and d-sarcoglycan were present in the
complex as one would expect under this SDS concentra-
tion (Fig. 5 a, lane 2). On the other hand, mouse myotubes
cross-linked with DTSSP resulted in co-immunoprecipita-
tion of all four sarcoglycans (Fig. 5 a, lane 3), indicating
that they were in close enough proximity to be cross-
linked and were located at the plasma membrane because
the cross-linking reagent used in the experiments is mem-
brane impermeable and can therefore only cross-link pro-
teins on the extracellular surface of the cells. However, not
all sarcoglycans were cross-linked to the same extent in
the experiments. Comparison of the amount of sarcogly-
cans being immunoprecipitated (Fig. 5 b, lane 3) to the
original input materials (lane 1) suggests that a-sarcogly-
can was less efficiently cross-linked to the complex relative
to other sarcoglycans.
In Vivo Cross-linked Sarcoglycans Consist of Two 
Major Subcomplexes
The status of the DTSSP cross-linked myotubes was exam-
ined in more detail by two-dimensional (2-D) diagonal gel
electrophoresis (Traut et al., 1989). The first dimension of
electrophoresis was performed under nonreducing condi-
Figure 4. Coimmunoprecip-
itation of the sarcoglycans
under different stringencies.
(A) Cell lysate from cultured
mouse myotubes was immu-
noprecipitated by the antiÐ
b-sarcoglycan antibody (NCLÐ
b-sarc). The immune complex
was washed in 1% NP-40
buffer containing no SDS
(lane  2), 0.2% SDS (lane 3),
0.3% SDS (lane 4), and 0.4%
SDS (lane 5). Lane 1, cell ly-
sate from mouse myotubes
(33% input). (B) Immuno-
precipitation was carried out
after cultured mouse myo-
tubes were lysed in 1% NP-40
buffer containing no SDS (lane 2), 0.1% SDS (lane 3), 0.2% SDS (lane 4), 0.3% SDS (lane 5), and 0.4% SDS (lane 6). Lane 1, cell lysate
from mouse myotubes (16% input). The final composition of the immune complex was determined by Western blots using antibodies
(18 Ab) against different sarcoglycans. Note that a-sarcoglycan was the most sensitive to increasing SDS concentration, resulting in dis-
sociation from the complex in both cases.
Figure 5. In vivo cross-linking of the sarcogly-
cans. Mouse myotubes were chemically cross-
linked with 1 mM DTSSP and immunoprecipitated
by antiÐb-sarcoglycan antibody (A) or antiÐa- or
b-dystroglycan antibody (B). Lane 1, cell lysate
from mouse myotubes (26Ð34% input). Lanes 2
and  4, immunoprecipitated products from un-
cross-linked myotubes. Lanes 3 and 5, immuno-
precipitated products from equal amount of
DTSSP cross-linked myotubes. The composition
of the immune complex was determined by West-
ern blots using antibodies (18 Ab) against differ-
ent sarcoglycans and dystroglycans.The Journal of Cell Biology, Volume 143, 1998 2038
tions and the second dimension of electrophoresis was
performed under reducing conditions. Proteins that are
not cross-linked will have the same electrophoretic mobil-
ity in both dimensions and will be detected on a diagonal
line in the gel. On the other hand, cross-linked proteins
will dissociate into their monomeric species in the second
dimension under reduction and will therefore appear be-
low the diagonal line (Fig. 6 a). By Western blot analysis,
both a- and b-dystroglycan were found to cross-link to
form a product of z200 kD in the first dimension (Fig. 6 b,
X) and upon reduction with DTT, they separated from
one another according to their molecular weights in the
second dimension (spot 1 and 2). This is consistent with
previous studies that a-dystroglycan was intimately associ-
ated with b-dystroglycan (Ibraghimov-Beskrovnaya et al.,
1992; Yoshida et al., 1994) and thus validated the use of
2-D diagonal gel to detect cross-linked proteins.
When a replicate blot was immunoblotted with the antiÐb-
and antiÐg-sarcoglycan antibodies, three spots were de-
tected below the diagonal line (Fig. 6 c). Two of the spots
were recognized by antibodies against b-sarcoglycan (spot
4a) and g-sarcoglycan (spot 5a) and together they were
cross-linked to form the product X1 of z120 kD. The third
spot was also recognized by the antiÐb-sarcoglycan anti-
body (spot 4b) but was cross-linked to form a smaller
product X2 of z80 kD. When the sum of the molecular
weight of the sarcoglycans identified in the cross-linked
species X1 was obtained (43 kD 1 35 kD 5 78 kD), there
was a missing mass of z40 kD in the product. Similarly,
when we added up the sum of the molecular weights of the
sarcoglycans identified in the cross-linked species X2 (43
kD 5 43 kD), there was also a missing mass of z40 kD.
Since d-sarcoglycan has a molecular weight of 35 kD, it is
possible that d-sarcoglycan could be part of the cross-
linked 120- and 80-kD complex. Western analysis of a rep-
licate blot using antiÐb- and antiÐd-sarcoglycan antibodies
revealed at least four spots below the diagonal line (Fig. 6
d, spots 4a, 4b, 6a, and 6b). Two of the spots (4a and 6a)
were recognized by the antiÐb- and antiÐd-sarcoglycan an-
tibody, respectively, and were shown to cross-link to form
the same 120-kD product (Fig. 6 d, X1) identified in Fig. 6
c. The other two spots (4b and 6b) were also recognized
by the antiÐb- and antiÐd-sarcoglycan antibodies, respec-
tively, and were cross-linked to form the same 80-kD
product (Fig. 6 d, X2) identified in Fig. 6 c. Intriguingly,
a-sarcoglycan was found to migrate as a single spot on the
diagonal line and did not seem to cross-link to any pro-
teins in these experiments (Fig. 6 b, spot III). Similar re-
sults were obtained when mouse myotubes were treated
with another cross-linker, sulfo-EGS which has a longer
spacer arm length (data not shown). Collectively, we have
demonstrated that b- and d-sarcoglycan could be cross-
linked to form two major subcomplexes (X1 and X2) in
which the 120-kD product X1 also consisted of g-sarcogly-
can. Our results suggest that both b- and d-sarcoglycan are
in close physical proximity and are consistent with our ear-
lier observations that they are tightly associated with one
another.
Figure 6. Analysis of the cross-linked sarcogly-
cans. Cell lysates from DTSSP cross-linked myo-
tubes were examined by 2-D diagonal gel using
antibodies against different sarcoglycans. (A)
Schematic diagram of the principle of 2-D diago-
nal gel. Single circle, uncross-linked proteins; two
circles  joined by a line, cross-linked product.
Shown in the examples are Western blots using
antibodies against a-sarcoglycan,  b- and a-dys-
troglycan (B), against b- and g-sarcoglycan (C),
and against b- and d-sarcoglycan (D). Cross-
linked proteins that appear below the diagonal
line are represented by Arabic numerals: 1, a-dys-
troglycan;  2,  b-dystroglycan;  4a and 4b, b-sar-
coglycan; 5a, g-sarcoglycan; and 6a, 6b, and 7,
d-sarcoglycan. The estimated molecular weight of
the three cross-linked products X, X1, and X2
identified in this experiment are z200, 120, and
80 kD, respectively. Note that not all sarco-
glycans and dystroglycans were cross-linked in
the experiments. Uncross-linked proteins were
found on the diagonal line and represented in
Roman numerals: I, a-dystroglycan; II, b-dystro-
glycan; III, a-sarcoglycan; IV, b-sarcoglycan; V,
g-sarcoglycan; and VI, d-sarcoglycan.Chan et al. Sarcoglycan Complex in Cultured Mouse Myotubes 2039
d-Sarcoglycan Can Be Cross-linked to the
Dystroglycan Complex
In the previous 2-D diagonal gel electrophoresis of DTSSP
cross-linked mouse myotubes, a third spot recognized by
the antiÐd-sarcoglycan antibody was sometimes observed
below the diagonal line (Fig. 6 d, spot 7). This spot was
cross-linked to form a product with an estimated molecu-
lar weight between 200Ð220 kD which is similar in size to
the cross-linked a-/b-dystroglycan complex identified in
Fig. 6 b. To determine if d-sarcoglycan could be cross-
linked to the dystroglycan complex, cell lysates from both
DTSSP cross-linked and uncross-linked mouse myotubes
were immunoprecipitated by antibodies against b-dystro-
glycan (Fig. 5 b, lanes 2 and 3) or a-dystroglycan (lane 4
and 5). Western analysis of the immune complex showed
a-dystroglycan was coprecipitated with b-dystroglycan from
both uncross-linked (lanes 2 and 4 ) and DTSSP cross-
linked myotube samples (lanes 3 and 5). No sarcoglycan
was found to be associated with the dystroglycans without
cross-linking (lanes 2 and 4), whereas both antibodies
immunoprecipitated  d-sarcoglycan from DTSSP cross-
linked myotube cell lysate (lanes 3 and 5). There was no
evidence that the immunoprecipitated materials contained
the other three sarcoglycans as revealed by Western blot
using antibodies against a-, b-, or g-sarcoglycan (lanes 2Ð5
and data not shown).
Sarcoglycans in Mouse Myotubes Form Intramolecular 
Disulfide Bonds
Sequence analysis of the sarcoglycans revealed that there
are clusters of conserved cysteine residues in their extra-
cellular domains which have the potential to form intra-
and/or intermolecular disulfide bonds (Fig. 7 a). To deter-
mine whether or not there are disulfide bonds in the
sarcoglycans, their electrophoretic mobility was compared
under reducing and nonreducing conditions using cell ly-
sates prepared from mouse myotubes. Western analysis
showed that b-, g-, d-sarcoglycan, and b-dystroglycan all
had a faster electrophoretic mobility under nonreducing
conditions (Fig. 7 b, lane 1, single arrowhead). This appar-
ent shift of mobility indicated the presence of intramolec-
ular disulfide bonds because proteins that contain such
disulfide bonds will often adapt a more compact confor-
mation and are expected to migrate faster in SDS-PAGE
gel under nonreducing conditions. This approach has been
used by others to demonstrate the presence of intramolec-
ular disulfide bonds in b-dystroglycan (Deyst et al., 1995).
No discernible difference in the electrophoretic mobility
was observed for a-sarcoglycan or the actin negative con-
trol.
The possibility of intermolecular disulfide bonds forma-
tion in sarcoglycans was examined by 2-D diagonal gel
method. The expectation would be that molecules linked
by disulfide bonds will migrate in the first dimension as a
large disulfide-linked complex and will dissociate into
monomers upon reduction in the second dimension. All
four sarcoglycans from mouse myotubes were detected on
the diagonal line (Fig. 8). Since no extra spot was detected
below the diagonal line, the sarcoglycans are not likely to
form disulfide bridges with other proteins in mouse myo-
tubes.
b- and g-Sarcoglycan Mutations Have Different Effects 
on the Sarcoglycan Complex
Although mutations in one sarcoglycan can disrupt the
sarcoglycan complex and lead to the loss or reduction
of other sarcoglycans, the degree of reduction of each
sarcoglycan observed in patients is often not the same. To
assess the effect of different sarcoglycan mutations on the
complex, we compared the immunostaining pattern of
Figure 7. Detection of intramolecular disulfide
bond in the sarcoglycans. (A) Alignment of the
carboxyl termini of b-,  g-,  d-, and C. elegans
sarcoglycan with the consensus EGF-like repeat
by MacVector Program (Oxford Molecular
Group, Oxford, UK). Right, numbers correspond
to the last amino acid residue in the protein; as-
terisk, stop codon; underline, four conserved cys-
teine residues. The cysteine 283 in g-sarcoglycan
(italics) is changed to tyrosine in patients with a
severe form of early onset autosomal recessive
muscular dystrophy (Piccolo et al., 1996). Ac-
cording to the consensus EGF-like repeat motif,
the fifth cysteine is linked to the sixth cysteine by
a disulfide bond (Abe et al., 1998). This corre-
sponds to the two middle conserved cysteine resi-
dues in the sarcoglycans. (B) Cell lysates from
cultured mouse myotubes were electrophoresed
in SDS-PAGE gel under nonreducing conditions
(lane 1) and reducing conditions (lane 2). After
transferred to nitrocellulose membranes, blots
were examined by Western using antibodies (18
Ab) against different sarcoglycans. The size of the sarcoglycans is indicated by a single arrow (nonreduced form) or a double arrow (re-
duced form). Note that the extra bands appearing on the nonreducing lane on the Western blot using the antiÐb-sarcoglycan antibody
were determined as nonspecific products unrelated to the DGC by 2-D diagonal gel electrophoresis (data not shown).The Journal of Cell Biology, Volume 143, 1998 2040
interact differently with one another or how these interac-
tions might be disturbed in muscular dystrophies. Coim-
munoprecipitation experiments from other groups have
suggested a high affinity interaction between b- and d-sar-
coglycan but the study was based on in vitro expressed
sarcoglycans (Sakamoto et al., 1997). Here we have ana-
lyzed the association of sarcoglycans using tissue culture
as a model system. In mouse cultured myotubes, the
sarcoglycans exist as a complex of proteins (Fig. 3) and are
intimately associated with dystrophin on the plasma mem-
brane (Figs. 1 and 2). Immunoprecipitation experiments
from cell lysates of these myotubes under increasingly
stringent conditions showed that the interaction between
b- and d-sarcoglycan is highly resistant to SDS (Fig. 4),
suggesting that they are tightly associated with one an-
other. In contrast, a-sarcoglycan can be dissociated from
the complex under relatively mild conditions (Fig. 4), im-
plying that its association with other sarcoglycans is rela-
tively weaker.
Previous cross-linking experiments by other groups us-
ing sarcoglycans purified from rabbit skeletal muscle have
identified two cross-linked products of 69 and 110 kD but
their exact compositions were not determined (Yoshida
et al., 1994). It has also been shown that a-sarcoglycan is
not readily cross-linked to other sarcoglycans (Yoshida
et al., 1994, 1997). In this report, when cultured mouse myo-
tubes were in vivo cross-linked with 1 mM DTSSP, two
major sarcoglycan subcomplexes of similar size (80 and
120 kD) were identified using 2-D diagonal gel electro-
phoresis (Fig. 6). Using a panel of sarcoglycan-specific an-
tibodies, we have demonstrated that the 120-kD product
consists of b-, g-, and d-sarcoglycan and the 80-kD product
contains b- and d-sarcoglycan. This preferential cross-link-
ing between b- and d-sarcoglycan provides additional sup-
port that they are the most tightly associated sarcoglycans.
There was no evidence of cross-linking between a-sar-
coglycan and other proteins as detected by the 2-D diago-
nal gel method, although coimmunoprecipitation experi-
ments have shown that a small amount of a-sarcoglycan
can be cross-linked to other sarcoglycans (Fig. 5 a). This
discordance is likely due to the low sensitivity of 2-D diag-
onal gel electrophoresis. All together, these results suggest
that a-sarcoglycan may be spatially separated from other
sarcoglycans.
Our results also showed that d-sarcoglycan was able to
cross-link to the dystroglycan complex. However, it is not
possible to distinguish to which of the two dystroglycans
d-sarcoglycan was cross-linked because the antiÐa- or
b-dystroglycan antibody used in this study resulted in
coimmunoprecipitation of both a- and b-dystroglycan and
d-sarcoglycan (Fig. 5 b). In the study of the BIO 14.6 ham-
ster model which has a deletion in the d-sarcoglycan gene,
there is not only a complete absence of all sarcoglycans but
also a dramatic reduction of a-dystroglycan (Holt et al.,
1998). Our data thus support a possible interaction be-
tween  d-sarcoglycan and the dystroglycan complex.
In our coimmunoprecipitation experiments, there was
a difference in the immunoprecipitation pattern of the
sarcoglycans with different anti-sarcoglycan antibodies
(Fig. 3). Although b-sarcoglycan was always coimmuno-
precipitated with d-sarcoglycan, a- and g-sarcoglycan were
often immunoprecipitated without the other sarcoglycans.
Figure 8. Absence of intermolecular disulfide bonds between the
sarcoglycans. Cell lysate from cultured mouse myotubes was elec-
trophoresed in 2-D diagonal gel and examined by Western blots
using antibodies against different sarcoglycans. Shown in the ex-
ample is the Western blot using antibodies against a-, b-, and
d-sarcoglycan. Note that no extra spot was observed below the di-
agonal line (dashed line).
sarcoglycans in two autosomal recessive muscular dystro-
phy patients with homozygous mutations in different
sarcoglycan genes. Both patients have a normal dystrophin
pattern at the muscle membrane as revealed by immuno-
histochemistry (Fig. 9). Patient AL has a homozygous
nonsense mutation that changes a tyrosine residue to a
premature stop codon at codon 178 in the b-sarcoglycan
(Bnnemann et al., 1998). This mutation is predicted to
produce a truncated protein z25 kD. Immunofluores-
cence studies showed that all four sarcoglycans were com-
pletely absent from the sarcolemma (Fig. 9). Patient CR,
on the other hand, carries a homozygous D521-T deletion
in the g-sarcoglycan gene. This patient has been previously
described in another report (Bnnemann et al., 1998). The
mutation has also been seen in other patients (McNally
et al., 1996) and is predicted to generate a truncated g-sar-
coglycan of z23 kD which is similar in size to the trun-
cated b-sarcoglycan. This patient showed a complete ab-
sence of g-sarcoglycan staining in the muscle biopsy by
immunofluorescence but the staining of the other three
sarcoglycans was preserved at a significant level (Fig. 9).
Discussion
The sarcoglycans are a group of four transmembrane pro-
teins which are part of the dystrophin-associated protein
complex at the sarcolemma. Mutations in the sarcoglycans
are responsible for four unique, yet clinically similar auto-
somal recessive forms of muscular dystrophy. Although it
is thought that mutations in one sarcoglycan can lead to
the disruption of the entire sarcoglycan complex, immuno-
histochemical studies and Western analyses have shown
that the effect of mutations on the complex is often depen-
dent on the particular sarcoglycan being mutated. This im-
plies that the molecular organization of the sarcoglycan
complex is more complicated than previously assumed.
Although several attempts have been made to understand
the organization of the sarcoglycans (Yoshida et al., 1994,
1997; Sakamoto et al., 1997), many of these studies have
not addressed the question of how each sarcoglycan mightChan et al. Sarcoglycan Complex in Cultured Mouse Myotubes 2041
Such a pattern is consistent with our findings that b-sar-
coglycan is preferentially associated with d-sarcoglycan
and  a-sarcoglycan is less strongly associated with other
sarcoglycans. However, the antibodies used in the experi-
ments might also play a role. Depending on the epitopes
recognized by these antibodies, the binding of the anti-
body to the sarcoglycan complex might be sterically hin-
dered or might disrupt existing interactions among the
sarcoglycans. It is worthwhile to note that both anti-
b-sarcoglycan and anti-human d-sarcoglycan antibodies
were raised against their intracellular domains and were
able to precipitate all four sarcoglycans from cultured myo-
tubes. The other three anti-sarcoglycan antibodies used in
this study were all directed against the extracellular por-
tion of the proteins and were only able to immunoprecipi-
tate one or two sarcoglycans. Thus, our results suggest that
the extracellular domain of the sarcoglycans might be im-
portant for their association. In support of this view, other
studies have shown that all four sarcoglycans interact with
one another via the extracellular but not intracellular do-
mains in an in vitro system (Sakamoto et al., 1997). More-
over, almost all mutations identified in the sarcoglycans
are in the extracellular domains of the respective proteins.
The Sarcoglycans As Two Distinct Subunits
Based on the above results, a structural model of the
sarcoglycan complex is proposed (Fig. 10). In this model,
the sarcoglycans are separated into two subunits: one con-
sisting of a-sarcoglycan and the other consisting of b-, g-,
and d-sarcoglycan in which the association between b- and
d-sarcoglycan is particularly strong. Structural analysis of
the sarcoglycans predicts that b-, g-, and d-sarcoglycan are
all type II transmembrane proteins (amino terminus on
Figure 9. Immunofluorescence of muscle biop-
sies from patients with autosomal recessive mus-
cular dystrophy. Muscle section was stained with
antibodies against dystrophin (dys), a-sarcogly-
can (a-sar), b-sarcoglycan (b-sar), g-sarcoglycan
(g-sar), and d-sarcoglycan (d-sar). Note that pa-
tients AL and CR showed different patterns of
immunostaining for each of the sarcoglycans.The Journal of Cell Biology, Volume 143, 1998 2042
the intracellular side) while a-sarcoglycan belongs to the
type I family (amino terminus on the extracellular side).
Sequence comparison between b-, g-, and d-sarcoglycan
also reveals they share significant homology with each
other and have the same number of amino acid residues
on the extracellular side (231 residues). Recently, an a-sar-
coglycan homologue, called e-sarcoglycan, has been iden-
tified (Ettinger et al., 1997; McNally et al., 1998). How-
ever, the level and the localization of the e-sarcoglycan
was shown to be normal in transgenic mice lacking either
a-sarcoglycan or g-sarcoglycan (Duclos et al., 1998b; Hack
et al., 1998). Our preliminary data also showed that e-sar-
coglycan did not coimmunoprecipitate with other sar-
coglycans, suggesting that it might not be an integral part
of the sarcoglycan complex (data not shown).
We have also identified intramolecular disulfide bonds
in b-, g-, and d-sarcoglycan (Fig. 7). Although a-sarcogly-
can did not show a shift of electrophoretic mobility under
nonreducing conditions, it has been suggested that it might
also have disulfide bonds based on the observation that
the binding of a monoclonal antibody specific to a-sar-
coglycan on immunoblots required nonreducing condi-
tions (Roberds et al., 1993). It is possible that the change
in the electrophoretic mobility might be too small to be
detected by our assay due to the different position of the
cysteine residues in a-sarcoglycan as opposed to the con-
served cysteines found at the carboxyl terminus of the
other sarcoglycans.
The exact cysteine residues that are involved in these
disulfide bonds were not determined here but sequence
analysis reveals that the last four cysteine residues located
at the carboxyl terminus of b-, g-, and d-sarcoglycan are
highly conserved (Fig. 7 a). The importance of these cys-
teine residues is demonstrated in a report that a missense
mutation in one of the conserved cysteines (C283Y) in
g-sarcoglycan is sufficient to cause the limb-girdle muscu-
lar dystrophy type 2C (Piccolo et al., 1996). Comparison to
other cysteine-rich motifs that are known to form intramo-
lecular disulfide bonds has shown that they belong to the
family of laminin-type EGF-like repeats commonly found
in many proteins such as laminin or the EGF receptor
(McNally et al., 1996). Since these proteins often exist as
oligomers and serve as receptors, it is possible that the b-,
g-, and d-sarcoglycan subunit also functions as a receptor
for an yet unidentified ligand. In this regard, they may actu-
ally resemble other receptor molecules on the cell surface
and potentially be part of a ligand-induced receptor signal-
ing pathway. a-Sarcoglycan, as a separate subunit, could be
the downstream effector. If this is the case, the sarcoglycan
complex could also be viewed as two distinct but interre-
lated functional subunits. In support of this hypothesis, the
DGC has been linked with other focal adhesion assembly
proteins such as integrins (Kramarcy and Sealock, 1990;
Lakonishok et al., 1992; Yoshida et al., 1998) and suggested
to function analogously to the integrins as a mechanochem-
ical transducer in skeletal muscle (Brown and Lucy, 1993).
Recently, an ecto-ATPase activity has been associated with
a-sarcoglycan (Salviati et al., 1997).
The Integrity of the Sarcoglycan Complex is Dependent 
on b- and d-Sarcoglycan
The tight association between b- and d-sarcoglycan raises
the possibility that they may form a functional core for the
assembly of the sarcoglycan complex as suggested earlier
by Bnnemann et al. (1996). According to our model, mu-
tations in either b- or d-sarcoglycan are expected to have a
profound effect on the sarcoglycan complex, whereas the
overall effect of a-sarcoglycan mutations on the complex
would be less disruptive since it is proposed to loosely as-
sociate with the other sarcoglycans and is possibly spatially
separated from others as well. The available immunofluo-
rescence and Western blot analyses of muscle biopsy sam-
ples taken from autosomal recessive muscular dystrophy
patients support this hypothesis. Of the small number re-
ported cases of patients with primary b- or d-sarcoglycan
mutations, they uniformly showed a complete absence or a
drastic reduction of all sarcoglycans at the sarcolemma
(Bnnemann et al., 1995, 1996, 1998; Lim et al., 1995;
Vainzof et al., 1996; Nigro et al., 1996a; Duclos et al.,
1998a). In contrast, patients with mutations in a- and
g-sarcoglycan often showed a reduced but, nevertheless,
detectable level of the other sarcoglycans by immunofluo-
rescence (McNally et al., 1996; Sewry et al., 1996; Carrie et
al., 1997; Barresi et al., 1997; Jones et al., 1998; Higuchi
et al., 1998). We were able to confirm this pattern of
sarcoglycan staining in two patients with similar homozy-
gous mutations and show that the effect of b- and g-sar-
coglycan mutations on the complex is different (Fig. 9).
Consistent with the model is that patients showing a com-
plete absence of just a- or g-sarcoglycan in their muscle bi-
opsies have been reported but patients missing only b- or
d-sarcoglycan have never been documented.
In conclusion, the combined use of immunoprecipitation
and cross-linking techniques provides a useful tool to dis-
sect the organization of the sarcoglycan complex. Such an
approach may also be useful in identifying new proteins
that associate with the DGC. Our structural model for the
sarcoglycan complex may enable us to predict the overall
Figure 10. Structural model of the sarcoglycan complex and the
dystroglycan complex. The four sarcoglycans (left) are repre-
sented by a, b, g, and d. a-DG and b-DG denote a- and b-dystro-
glycan (right), respectively. Branch structure corresponds to
N-glycoside sugar chain. SH, disulfide linkage. Double-headed ar-
row, potential interaction between d-sarcoglycan and the dystro-
glycan complex. In the model, b-sarcoglycan is tightly associated
with  d-sarcoglycan.  a-Sarcoglycan is placed apart from other
sarcoglycans and is viewed as a separate subunit within the
sarcoglycan complex.Chan et al. Sarcoglycan Complex in Cultured Mouse Myotubes 2043
effect of specific sarcoglycan mutations on the complex
and perhaps explain the correlation between the genotype
and the phenotype of patients, including the immunohis-
tochemical findings. The molecular characterization of the
sarcoglycans may provide important information on the
possible functions of the sarcoglycans and thus the patho-
genesis of muscular dystrophy.
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